224 related articles for article (PubMed ID: 38491408)
1. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract][Full Text] [Related]
2. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
4. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
5. Proteogenomic and metabolomic characterization of human glioblastoma.
Wang LB; Karpova A; Gritsenko MA; Kyle JE; Cao S; Li Y; Rykunov D; Colaprico A; Rothstein JH; Hong R; Stathias V; Cornwell M; Petralia F; Wu Y; Reva B; Krug K; Pugliese P; Kawaler E; Olsen LK; Liang WW; Song X; Dou Y; Wendl MC; Caravan W; Liu W; Cui Zhou D; Ji J; Tsai CF; Petyuk VA; Moon J; Ma W; Chu RK; Weitz KK; Moore RJ; Monroe ME; Zhao R; Yang X; Yoo S; Krek A; Demopoulos A; Zhu H; Wyczalkowski MA; McMichael JF; Henderson BL; Lindgren CM; Boekweg H; Lu S; Baral J; Yao L; Stratton KG; Bramer LM; Zink E; Couvillion SP; Bloodsworth KJ; Satpathy S; Sieh W; Boca SM; Schürer S; Chen F; Wiznerowicz M; Ketchum KA; Boja ES; Kinsinger CR; Robles AI; Hiltke T; Thiagarajan M; Nesvizhskii AI; Zhang B; Mani DR; Ceccarelli M; Chen XS; Cottingham SL; Li QK; Kim AH; Fenyö D; Ruggles KV; Rodriguez H; Mesri M; Payne SH; Resnick AC; Wang P; Smith RD; Iavarone A; Chheda MG; Barnholtz-Sloan JS; Rodland KD; Liu T; Ding L;
Cancer Cell; 2021 Apr; 39(4):509-528.e20. PubMed ID: 33577785
[TBL] [Abstract][Full Text] [Related]
6. The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.
Ohka F; Natsume A; Motomura K; Kishida Y; Kondo Y; Abe T; Nakasu Y; Namba H; Wakai K; Fukui T; Momota H; Iwami K; Kinjo S; Ito M; Fujii M; Wakabayashi T
PLoS One; 2011; 6(8):e23332. PubMed ID: 21829728
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic significance of TCTN1 in human glioblastoma.
Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
Park J; Shim JK; Yoon SJ; Kim SH; Chang JH; Kang SG
Sci Rep; 2019 Jul; 9(1):10555. PubMed ID: 31332251
[TBL] [Abstract][Full Text] [Related]
10. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma.
Cho HJ; Zhao J; Jung SW; Ladewig E; Kong DS; Suh YL; Lee Y; Kim D; Ahn SH; Bordyuh M; Kang HJ; Sa JK; Seo YJ; Kim ST; Lim DH; Dho YS; Lee JI; Seol HJ; Choi JW; Park WY; Park CK; Rabadan R; Nam DH
Neuro Oncol; 2019 Jan; 21(1):47-58. PubMed ID: 30085274
[TBL] [Abstract][Full Text] [Related]
11. Multi-Omics Data Integration and Mapping of Altered Kinases to Pathways Reveal Gonadotropin Hormone Signaling in Glioblastoma.
Jayaram S; Gupta MK; Raju R; Gautam P; Sirdeshmukh R
OMICS; 2016 Dec; 20(12):736-746. PubMed ID: 27930095
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
13. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol.
O'Regan CJ; Kearney H; Beausang A; Farrell MA; Brett FM; Cryan JB; Loftus TE; Buckley PG
J Neurooncol; 2018 Apr; 137(2):233-240. PubMed ID: 29264834
[TBL] [Abstract][Full Text] [Related]
14. TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
Zhang X; Katsakhyan L; LiVolsi VA; Roth JJ; Rassekh CH; Bagley SJ; Nasrallah MP
Am J Surg Pathol; 2021 Nov; 45(11):1516-1526. PubMed ID: 34366423
[TBL] [Abstract][Full Text] [Related]
15. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
16. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.
Das P; Puri T; Jha P; Pathak P; Joshi N; Suri V; Sharma MC; Sharma BS; Mahapatra AK; Suri A; Sarkar C
J Clin Neurosci; 2011 Jan; 18(1):66-70. PubMed ID: 20888234
[TBL] [Abstract][Full Text] [Related]
17. Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
Schiffgens S; Wilkens L; Brandes AA; Meier T; Franceschi E; Ermani M; Hartmann C; Sandalcioglu IE; Dumitru CA
Oncotarget; 2016 Aug; 7(34):55169-55180. PubMed ID: 27409829
[TBL] [Abstract][Full Text] [Related]
18. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
19. The somatic genomic landscape of glioblastoma.
Brennan CW; Verhaak RG; McKenna A; Campos B; Noushmehr H; Salama SR; Zheng S; Chakravarty D; Sanborn JZ; Berman SH; Beroukhim R; Bernard B; Wu CJ; Genovese G; Shmulevich I; Barnholtz-Sloan J; Zou L; Vegesna R; Shukla SA; Ciriello G; Yung WK; Zhang W; Sougnez C; Mikkelsen T; Aldape K; Bigner DD; Van Meir EG; Prados M; Sloan A; Black KL; Eschbacher J; Finocchiaro G; Friedman W; Andrews DW; Guha A; Iacocca M; O'Neill BP; Foltz G; Myers J; Weisenberger DJ; Penny R; Kucherlapati R; Perou CM; Hayes DN; Gibbs R; Marra M; Mills GB; Lander E; Spellman P; Wilson R; Sander C; Weinstein J; Meyerson M; Gabriel S; Laird PW; Haussler D; Getz G; Chin L;
Cell; 2013 Oct; 155(2):462-77. PubMed ID: 24120142
[TBL] [Abstract][Full Text] [Related]
20. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
